DOCSLIB.ORG

Impact of Genetic Variants of RFC1, DHFR and MTHFR in Osteosarcoma Patients Treated with High-Dose Methotrexate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Impact of Genetic Variants of RFC1, DHFR and MTHFR in Osteosarcoma Patients Treated with High-Dose Methotrexate The Pharmacogenomics Journal (2015) 15, 385–390 © 2015 Macmillan Publishers Limited All rights reserved 1470-269X/15 www.nature.com/tpj ORIGINAL ARTICLE Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate S Jabeen1,2, L Holmboe3, GIG Alnæs2,4, AM Andersen5, KS Hall6 and VN Kristensen1,2,4 Osteosarcoma patients are commonly treated with high doses of methotrexate (MTX). MTX is an analog of folate, which is essential for DNA synthesis. Genetic polymorphism at single nucleotide can be indicative to the prognostic outcome in patients. Germ-line variants in candidate genes, coding for enzymes active in the metabolism of MTX, were studied in 62 osteosarcoma patients. Patients harboring the GG genotype in reduced folate carrier 1 (RFC1) rs1051266 had significantly better survival in comparison with patients having the AA genotype (P = 0.046). These patients also had a lower frequency of metastasis (15%, P = 0.029). Also patients homozygous for the G allele of rs1053129 in the dihydrofolate reductase (DHFR) gene were more likely to have a metastasis (45%, P = 0.005), and the methylenetetetrahydrofolate reductase (MTHFR) 677C allele was associated with higher degree of liver toxicity (88%, P = 0.007). The study suggests that germ-line variants in the MTX metabolic pathway are associated with survival and side effects in patients treated with MTX. The Pharmacogenomics Journal (2015) 15, 385–390; doi:10.1038/tpj.2015.11; published online 17 March 2015 INTRODUCTION Intracellular MTX is converted to polyanionic polyglutamates Methotrexate (MTX) is a folate analog used in the treatment of (PGMTX), which creates a gradient for continual cellular uptake of 11,12 autoimmune diseases and cancers such as osteosarcoma. Bone folates and folate analogs. Accumulated intracellular MTX and sarcomas such as osteosarcoma constitute approximately 0.2% of PGMTX interact with dihydrofolate reductase (DHFR), the enzyme all cancers. Of the approximately 40 new bone sarcomas that converts dihydrofolate (DHF) to tetrahydrofolate (THF), which 13,14 diagnosed each year in Norway 12–15 will be osteosarcoma.1 is essential for de novo purine synthesis. Osteosarcoma patients show a bimodal age distribution with a Treatment response mainly depends on the route of adminis- first peak during adolescence and a second peak in older tration, dose and duration of treatment. Response may also be adulthood.2 The second incidence peak in the elderly typically influenced by the activity of the proteins related to MTX uptake, appears in previously irradiated areas or is secondary to Paget’s and genetic variation in the genes coding for these proteins may disease.3 The current standard treatment for osteosarcoma is neo- affect their production or function. Therefore, we analyzed single- adjuvant chemotherapy given before surgery with a high-dose nucleotide polymorphisms (SNPs) and repeat polymorphisms in methotrexate (HDMTX) and subsequent leucovorin rescue, dox- key metabolic genes of the MTX pathway: RFC1, the major influx orubicin and/or cisplatin followed by surgical resection. A major pump; DHFR, the main target of MTX and PGMTX; methylene- challenge of HDMTX therapy is the great interpatient variability in tetetrahydrofolate reductase (MTHFR), en enzyme from the folate clinical response. Bielack et al.4 observed that over 40% of the metabolism pathway and ATP-binding cassette, sub-family G, patients showed poor response to chemotherapy-related treat- member 2 (ABCG2), one of the major MTX efflux pumps. ment, in a study where a good response was defined as less than 10% viable tumor. The wide spectrum of side effects during HDMTX treatment may include gastrointestinal disturbances, MATERIALS AND METHODS alopecia, elevated levels of liver enzymes, bone-marrow suppres- Patient material 5–7 sion and renal toxicity. Serum concentrations of MTX are Serum samples were available for 62 HDMTX-treated osteosarcoma monitored and used to adjust leucovorin rescue to prevent patients with detailed pharmacokinetic and genetic data (see below). toxicity. The patients were treated at The Norwegian Radium Hospital between MTX interacts with a number of enzymes of the folate metabolic 1994 and 2003. pathway. Folate is essential for the synthesis of DNA nucleotides, All treatment protocols in this study were multi-drug regimens most notably thymine, but also the purine bases. MTX enters cells consisting of HDMTX, cisplatin, doxorubicin and ifosfamide, and in some through three possible routes. The major route is via reduced patients, additional etoposide was administered. folate carrier 1 (RFC1).8–10 Reduced or altered expression of the proteins related to MTX uptake, commonly seen in malignant cells, Approvals may be another cause of altered transport kinetics of MTX into the The study protocol was approved by the Regional Ethics Committee. cells.9 Written informed consent was obtained from all participants. Studies on 1Division of Medicine, Department for Clinical Molecular Biology and Lab Science (EpiGen), Akershus University Hospital, Lørenskog, Norway; 2KG Jebsen Center for Breast Cancer Research, Department of Genetics, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; 3Department of Nuclear Medicine, Oslo University Hospital Ullevål, Oslo, Norway; 4Division of Cancer Surgery and Transplantation, Department of Genetics, Institute for Cancer Research, OUS HF, Radiumhospitalet, Oslo, Norway; 5Department of Pharmacology, Oslo University Hospital, Rikshospitalet, Oslo, Norway and 6Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway. Correspondence: Professor V Kristensen, Clinical Molecular Biology, University of Oslo, P. B. 28, Lorenskog 1478, Norway. E-mail: [email protected] Received 22 August 2014; revised 13 January 2015; accepted 28 January 2015; published online 17 March 2015 SNPs and methotrexate treatment of osteosarcoma S Jabeen et al 386 human participants were approved according to the Declaration of Haploview was also used to estimate Hardy–Weinberg equilibrium for Helsinki (http://www.wma.net/e/policy/b3.htm). the genotypes, as a control for technical genotyping errors and biases in the selection of study populations. MTX treatment Genotype frequencies of SNPs and haplotypes were compared to binary variables with the Pearson’s chi square (χ2) test implemented in Patients were treated with MTX as a 4-h infusion with leucovorin rescue Haploview.17 The resulting associations were permuted 1000 times to started 24 h after initiation of MTX as described by Holmboe et al.15 obtain a measure of significance corrected for multiple testing. The results Evaluation of efficacy and toxicity was assessed by case note review were also verified by Pearson χ2 analysis in SPSS. We used statistical from three independent investigators (KRH, JRFC and DPJ), blinded for packages R version 2.5 (r-project.org) and SPSS (v13. CA, USA), unless genotyping results. otherwise stated. Since in the studied cases the actual underlying mode of inheritance of the causal allele was unknown, the co-dominant model, a DNA isolation single two degrees of freedom test, was shown to have a good overall DNA was isolated from serum samples using the QIAamp® DNA Mini kit performance19 and was applied here. ANOVA was applied to examine (Qiagen, Hilden, Germany) following suppliers specifications. The provided continuous versus categorical variables for clinical metabolic data versus spin-columns were loaded with 200 μl proteinase-treated serum, and DNA SNP frequencies. After Bonferroni correction for six tests (since two pairs of was cleaned with ethanol before eluted in 200 μl DNase-free water. SNPs were in LD), a P-value of 0.008 was considered as significant and presented in the paper. For survival analysis Kaplan–Meier analysis was Genotyping of SNP used to test association between three possible genotypes for each SNP and patient survival times. Log-rank test with P-value under 0.05 was SNPs: RCF1 rs1051266, DHFR rs1053129, DHFR rs1650723, DHFR rs1677666, considered as significant. MTHFR rs1801133, MTHFR rs1801131, ABCG2 rs2231135 and ABCG2 rs2231142 were genotyped on the Nanogen Molecular Biology Workstation 16 platform (Nanogen, San Diego, CA, USA) as described in Nordgard et al. RESULTS The accuracy of genotyping on Nanogen has previously been evaluated, and, with regard to both success and error rate, found comparable to the Polymorphism in RFC1 showed association with survival other platforms assayed, such as TaqMan, SNPstream and MassArray3. The major influx transporter of MTX, RFC1, is encoded by the fi Further, the genotypes obtained with Nanogen were veri ed by solute carrier family 19, member 1. Downregulation of RFC1 has sequencing and a perfect match (100%) to the genotype calls was been reported to be associated with impaired MTX transport and observed. resistance.20–22 We genotyped rs1051266 in exon 2, a well-studied, non-synonymous polymorphism (80G4A) that results in substitu- Metabolic data tion of a histidine for an arginine at residue 27 of the protein MTX and its major extracellular metabolite 7-OH-MTX were measured (Arg27His). A log-rank test for Kaplan–Meier analysis for GG versus in 8 serum samples per HDMTX cycle in 62 consecutive osteosarcoma AA showed that the patients homozygous for the G allele of RFC1 patients. Alanine aminotransferase (ALAT), alkaline phosphatase, gamma- fi glutamyltransferase and total bilirubin were measured in the same serum rs1051266
Load more

Recommended publications
  • Regulates Cellular Telomerase Activity by Methylation of TERT Promoter
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 5), pp: 7977-7988 Research Paper Tianshengyuan-1 (TSY-1) regulates cellular Telomerase activity by methylation of TERT promoter Weibo Yu1, Xiaotian Qin2, Yusheng Jin1, Yawei Li2, Chintda Santiskulvong3, Victor Vu1, Gang Zeng4,5, Zuofeng Zhang6, Michelle Chow1, Jianyu Rao1,5 1Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA 2Beijing Boyuantaihe Biological Technology Co., Ltd., Beijing, China 3Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA 4Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA 5Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA, USA 6Department of Epidemiology, School of Public Health, University of California at Los Angeles, Los Angeles, CA, USA Correspondence to: Jianyu Rao, email: [email protected] Keywords: TSY-1, hematopoietic cells, Telomerase, TERT, methylation Received: September 08, 2016 Accepted: November 24, 2016 Published: December 15, 2016 ABSTRACT Telomere and Telomerase have recently been explored as anti-aging and anti- cancer drug targets with only limited success. Previously we showed that the Chinese herbal medicine Tianshengyuan-1 (TSY-1), an agent used to treat bone marrow deficiency, has a profound effect on stimulating Telomerase activity in hematopoietic cells. Here, the mechanism of TSY-1 on cellular Telomerase activity was further investigated using HL60, a promyelocytic leukemia cell line, normal peripheral blood mononuclear cells, and CD34+ hematopoietic stem cells derived from umbilical cord blood. TSY-1 increases Telomerase activity in normal peripheral blood mononuclear cells and CD34+ hematopoietic stem cells with innately low Telomerase activity but decreases Telomerase activity in HL60 cells with high intrinsic Telomerase activity, both in a dose-response manner.
    [Show full text]
  • A New Class of Disordered Elements Controls DNA Replication Through
    RESEARCH ARTICLE A new class of disordered elements controls DNA replication through initiator self-assembly Matthew W Parker1,2, Maren Bell2, Mustafa Mir2, Jonchee A Kao2, Xavier Darzacq2, Michael R Botchan2*, James M Berger1* 1Department of Biophysics and Biophysical Chemistry, Johns Hopkins School of Medicine, Baltimore, United States; 2Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States Abstract The initiation of DNA replication in metazoans occurs at thousands of chromosomal sites known as origins. At each origin, the Origin Recognition Complex (ORC), Cdc6, and Cdt1 co- assemble to load the Mcm2-7 replicative helicase onto chromatin. Current replication models envisage a linear arrangement of isolated origins functioning autonomously; the extent of inter- origin organization and communication is unknown. Here, we report that the replication initiation machinery of D. melanogaster unexpectedly undergoes liquid-liquid phase separation (LLPS) upon binding DNA in vitro. We find that ORC, Cdc6, and Cdt1 contain intrinsically disordered regions (IDRs) that drive LLPS and constitute a new class of phase separating elements. Initiator IDRs are shown to regulate multiple functions, including chromosome recruitment, initiator-specific co- assembly, and Mcm2-7 loading. These data help explain how CDK activity controls replication initiation and suggest that replication programs are subject to higher-order levels of inter-origin organization. DOI: https://doi.org/10.7554/eLife.48562.001 *For
    [Show full text]
  • Sequence Variation in the Dihydrofolate Reductase-Thymidylate Synthase (DHFR-TS) and Trypanothione Reductase (TR) Genes of Trypanosoma Cruzi
    Molecular & Biochemical Parasitology 121 (2002) 33Á/47 www.parasitology-online.com Sequence variation in the dihydrofolate reductase-thymidylate synthase (DHFR-TS) and trypanothione reductase (TR) genes of Trypanosoma cruzi Carlos A. Machado *, Francisco J. Ayala Department of Ecology and Evolutionary Biology, University of California, Irvine, CA 92697-2525, USA Received 15 November 2001; received in revised form 25 January 2002 Abstract Dihydrofolate reductase-thymidylate synthase (DHFR-TS) and trypanothione reductase (TR) are important enzymes for the metabolism of protozoan parasites from the family Trypanosomatidae (e.g. Trypanosoma spp., Leishmania spp.) that are targets of current drug-design studies. Very limited information exists on the levels of genetic polymorphism of these enzymes in natural populations of any trypanosomatid parasite. We present results of a survey of nucleotide variation in the genes coding for those enzymes in a large sample of strains from Trypanosoma cruzi, the agent of Chagas’ disease. We discuss the results from an evolutionary perspective. A sample of 31 strains show 39 silent and five amino acid polymorphisms in DHFR-TS, and 35 silent and 11 amino acid polymorphisms in TR. No amino acid replacements occur in regions that are important for the enzymatic activity of these proteins, but some polymorphisms occur in sites previously assumed to be invariant. The sequences from both genes cluster in four major groups, a result that is not fully consistent with the current classification of T. cruzi in two major groups of strains. Most polymorphisms correspond to fixed differences among the four sequence groups. Two tests of neutrality show that there is no evidence of adaptivedivergence or of selectiveevents having shaped the distribution of polymorphisms and fixed differences in these genes in T.
    [Show full text]
  • Supplementary Table S1. Correlation Between the Mutant P53-Interacting Partners and PTTG3P, PTTG1 and PTTG2, Based on Data from Starbase V3.0 Database
    Supplementary Table S1. Correlation between the mutant p53-interacting partners and PTTG3P, PTTG1 and PTTG2, based on data from StarBase v3.0 database. PTTG3P PTTG1 PTTG2 Gene ID Coefficient-R p-value Coefficient-R p-value Coefficient-R p-value NF-YA ENSG00000001167 −0.077 8.59e-2 −0.210 2.09e-6 −0.122 6.23e-3 NF-YB ENSG00000120837 0.176 7.12e-5 0.227 2.82e-7 0.094 3.59e-2 NF-YC ENSG00000066136 0.124 5.45e-3 0.124 5.40e-3 0.051 2.51e-1 Sp1 ENSG00000185591 −0.014 7.50e-1 −0.201 5.82e-6 −0.072 1.07e-1 Ets-1 ENSG00000134954 −0.096 3.14e-2 −0.257 4.83e-9 0.034 4.46e-1 VDR ENSG00000111424 −0.091 4.10e-2 −0.216 1.03e-6 0.014 7.48e-1 SREBP-2 ENSG00000198911 −0.064 1.53e-1 −0.147 9.27e-4 −0.073 1.01e-1 TopBP1 ENSG00000163781 0.067 1.36e-1 0.051 2.57e-1 −0.020 6.57e-1 Pin1 ENSG00000127445 0.250 1.40e-8 0.571 9.56e-45 0.187 2.52e-5 MRE11 ENSG00000020922 0.063 1.56e-1 −0.007 8.81e-1 −0.024 5.93e-1 PML ENSG00000140464 0.072 1.05e-1 0.217 9.36e-7 0.166 1.85e-4 p63 ENSG00000073282 −0.120 7.04e-3 −0.283 1.08e-10 −0.198 7.71e-6 p73 ENSG00000078900 0.104 2.03e-2 0.258 4.67e-9 0.097 3.02e-2 Supplementary Table S2.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Methotrexate Inhibits the First Committed Step of Purine
    Biochem. J. (1999) 342, 143–152 (Printed in Great Britain) 143 Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Lynette D. FAIRBANKS*, Katarzyna RU$ CKEMANN*1, Ying QIU*2, Catherine M. HAWRYLOWICZ†, David F. RICHARDS†, Ramasamyiyer SWAMINATHAN‡, Bernhard KIRSCHBAUM§ and H. Anne SIMMONDS*3 *Purine Research Laboratory, 5th Floor Thomas Guy House, GKT Guy’s Hospital, London Bridge, London SE1 9RT, U.K., †Department of Respiratory Medicine and Allergy, 5th Floor Thomas Guy House, GKT Guy’s Hospital, London Bridge, London SE1 9RT, U.K., ‡Department of Chemical Pathology, GKT Guy’s Hospital, London Bridge, London SE1 9RT, U.K., and §DG Rheumatic/Autoimmune Diseases, Hoechst Marion Roussel, Deutschland GmbH, D-65926 Frankfurt am Main, Germany The immunosuppressive and anti-inflammatory effects of low- ribosyl-1-pyrophosphate (PP-ribose-P) as the molecular mech- dose methotrexate (MTX) have been related directly to inhibition anism underlying these disparate changes. These results provide of folate-dependent enzymes by polyglutamated derivatives, or the first substantive evidence that the immunosuppressive effects indirectly to adenosine release and\or apoptosis and clonal of low-dose MTX in primary blasting human T-lymphocytes deletion of activated peripheral blood lymphocytes in S-phase. In relate not to the inhibition of the two folate-dependent enzymes this study of phytohaemagglutinin-stimulated primary human T- of purine biosynthesis but to inhibition of the first enzyme, lymphocytes we show that MTX (20 nM to 20 µM) was cytostatic amidophosphoribosyltransferase, thereby elevating PP-ribose-P not cytotoxic, halting proliferation at G".
    [Show full text]
  • DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents
    molecules Review DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents Maria Valeria Raimondi 1,*,† , Ornella Randazzo 1,†, Mery La Franca 1 , Giampaolo Barone 1 , Elisa Vignoni 2, Daniela Rossi 2 and Simona Collina 2,* 1 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, 90123 Palermo, Italy; [email protected] (O.R.); [email protected] (M.L.F.); [email protected] (G.B.) 2 Drug Sciences Department, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia, via Taramelli 12, 27100 Pavia, Italy; [email protected] (E.V.); [email protected] (D.R.) * Correspondence: [email protected] (M.V.R.); [email protected] (S.C.); Tel.: +390-912-389-1915 (M.V.R.); +390-382-987-379 (S.C.) † These Authors contributed equally to this work. Academic Editors: Simona Collina and Mariarosaria Miloso Received: 25 February 2019; Accepted: 20 March 2019; Published: 22 March 2019 Abstract: Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their use as antibacterial, antimalarial, antifungal, and anticancer agents. Progress in understanding the biochemical basis of mechanisms responsible for enzyme selectivity and antiproliferative effects has renewed the interest in antifolates for cancer chemotherapy and prompted the medicinal chemistry community to develop novel and selective human DHFR inhibitors, thus leading to a new generation of DHFR inhibitors. This work summarizes the mechanism of action, chemical, and anticancer profile of the DHFR inhibitors discovered in the last six years. New strategies in DHFR drug discovery are also provided, in order to thoroughly delineate the current landscape for medicinal chemists interested in furthering this study in the anticancer field.
    [Show full text]
  • 1611 REGULATION of PYRIMIDINE METABOLISM in PLANTS Chris
    [Frontiers in Bioscience 9, 1611-1625, May 1, 2004] REGULATION OF PYRIMIDINE METABOLISM IN PLANTS 1, 2 1, 3 1, 4 1, 5 1, 6 1, 7 Chris Kafer , Lan Zhou , Djoko Santoso , Adel Guirgis , Brock Weers , Sanggyu Park and Robert Thornburg 1 1 Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, Iowa 50011, 2 BASF Plant Science LLC, 2901 South Loop Drive, Ste 3800, Ames, Iowa 50014, 3 Lan Zhou, Pioneer Hi-Bred International, Inc. 7300 NW 62nd Avenue, PO Box 1004, Johnston, Iowa 50131-1004, 4 Indonesian Biotechnology Research Institute for Estate Crops, Jl, Taman Kencana No 1, Bogor 16151 Indonesia, 5 Institute of Genetic Engineering and Biotechnology, Menofiya University, PO Box 79/22857, Sadat City, Egypt, 6 Department of Biochemistry, University of Iowa, 4/511 Bowen Science Building, Iowa City, Iowa 52242-1109, 7 Division of Life and Environment, College of Natural Resources, Daegu University, Gyongsan City, Gyongbuk, Korea 712-714 TABLE OF CONTENTS 1. Abstract 2. Introduction 3. Pyrimidine metabolic pathways 3.1. De novo pyrimidine biosynthesis 3.1.1. CPSase 3.1.2. ATCase 3.1.3. DHOase 3.1.4. DHODH 3.1.5. UMPS 3.1.6. Intracellular Organization of the de novo Pathway 3.2. Pyrimidine Salvage and Recycling 3.2.1. Cytosine deaminase 3.2.2. Cytidine deaminase 3.2.3. UPRTase 3.3. Pyrimidine Modification 3.3.1. UMP/CMP kinase 3.3.2. NDP kinase 3.3.3. CTP synthase, NDP reductase, dUTPase 3.3.4. Thymidylate synthase/Dihydrofolate reductase 3.4. Pyrimidine Catabolism 4. Regulation of pyrimidine metabolism 4.1.
    [Show full text]
  • NADPH Homeostasis in Cancer: Functions, Mechanisms and Therapeutic Implications
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications Huai-Qiang Ju 1,2, Jin-Fei Lin1, Tian Tian1, Dan Xie 1 and Rui-Hua Xu 1,2 Nicotinamide adenine dinucleotide phosphate (NADPH) is an essential electron donor in all organisms, and provides the reducing power for anabolic reactions and redox balance. NADPH homeostasis is regulated by varied signaling pathways and several metabolic enzymes that undergo adaptive alteration in cancer cells. The metabolic reprogramming of NADPH renders cancer cells both highly dependent on this metabolic network for antioxidant capacity and more susceptible to oxidative stress. Modulating the unique NADPH homeostasis of cancer cells might be an effective strategy to eliminate these cells. In this review, we summarize the current existing literatures on NADPH homeostasis, including its biological functions, regulatory mechanisms and the corresponding therapeutic interventions in human cancers, providing insights into therapeutic implications of targeting NADPH metabolism and the associated mechanism for cancer therapy. Signal Transduction and Targeted Therapy (2020) 5:231; https://doi.org/10.1038/s41392-020-00326-0 1234567890();,: BACKGROUND for biosynthetic reactions to sustain their rapid growth.5,11 This In cancer cells, the appropriate levels of intracellular reactive realization has prompted molecular studies of NADPH metabolism oxygen species (ROS) are essential for signal transduction and and its exploitation for the development of anticancer agents. cellular processes.1,2 However, the overproduction of ROS can Recent advances have revealed that therapeutic modulation induce cytotoxicity and lead to DNA damage and cell apoptosis.3 based on NADPH metabolism has been widely viewed as a novel To prevent excessive oxidative stress and maintain favorable and effective anticancer strategy.
    [Show full text]
  • Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Anti
    JPET Fast Forward. Published on February 2, 2018 as DOI: 10.1124/jpet.117.246199 This article has not been copyedited and formatted. The final version may differ from this version. JPET #246199 Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Anti- proliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP Rakesh K. Singh, Leon van Haandel, Daniel P. Heruth, Shui Q. Ye, J. Steven Leeder, Mara L. Becker, Ryan S. Funk Department of Pharmacy Practice, The University of Kansas Medical Center, Kansas City, KS Downloaded from 66160 (RKS and RSF) Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children’s Mercy jpet.aspetjournals.org Kansas City, Kansas City, MO 64108 (LVH, JSL, and MLB) Division of Rheumatology, Children’s Mercy Kansas City, Kansas City, MO 64108 (MLB) Division of Experimental and Translational Genetics, Children’s Mercy Kansas City, Kansas at ASPET Journals on September 27, 2021 City, MO 64108 (DPH and SQY) Department of Pharmacology, Toxicology, and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160 (JSL and RSF) Department of Biomedical and Health Informatics, University of Missouri Kansas City School of Medicine, Kansas City, Kansas City, MO 64108 (SQY) 1 JPET Fast Forward. Published on February 2, 2018 as DOI: 10.1124/jpet.117.246199 This article has not been copyedited and formatted. The final version may differ from this version. JPET #246199 Running title: NAMPT Deficiency Potentiates ATP Depletion by Methotrexate Corresponding
    [Show full text]
  • Arsenic Hexoxide Has Differential Effects on Cell Proliferation And
    www.nature.com/scientificreports OPEN Arsenic hexoxide has diferential efects on cell proliferation and genome‑wide gene expression in human primary mammary epithelial and MCF7 cells Donguk Kim1,7, Na Yeon Park2,7, Keunsoo Kang3, Stuart K. Calderwood4, Dong‑Hyung Cho2, Ill Ju Bae5* & Heeyoun Bunch1,6* Arsenic is reportedly a biphasic inorganic compound for its toxicity and anticancer efects in humans. Recent studies have shown that certain arsenic compounds including arsenic hexoxide (AS4O6; hereafter, AS6) induce programmed cell death and cell cycle arrest in human cancer cells and murine cancer models. However, the mechanisms by which AS6 suppresses cancer cells are incompletely understood. In this study, we report the mechanisms of AS6 through transcriptome analyses. In particular, the cytotoxicity and global gene expression regulation by AS6 were compared in human normal and cancer breast epithelial cells. Using RNA‑sequencing and bioinformatics analyses, diferentially expressed genes in signifcantly afected biological pathways in these cell types were validated by real‑time quantitative polymerase chain reaction and immunoblotting assays. Our data show markedly diferential efects of AS6 on cytotoxicity and gene expression in human mammary epithelial normal cells (HUMEC) and Michigan Cancer Foundation 7 (MCF7), a human mammary epithelial cancer cell line. AS6 selectively arrests cell growth and induces cell death in MCF7 cells without afecting the growth of HUMEC in a dose‑dependent manner. AS6 alters the transcription of a large number of genes in MCF7 cells, but much fewer genes in HUMEC. Importantly, we found that the cell proliferation, cell cycle, and DNA repair pathways are signifcantly suppressed whereas cellular stress response and apoptotic pathways increase in AS6‑treated MCF7 cells.
    [Show full text]
  • Dihydropyrimidine Dehydrogenase in the Metabolism of the Anticancer Drugs
    Cancer Chemotherapy and Pharmacology (2019) 84:1157–1166 https://doi.org/10.1007/s00280-019-03936-w REVIEW ARTICLE Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs Vinay Sharma1 · Sonu Kumar Gupta1 · Malkhey Verma1 Received: 3 May 2019 / Accepted: 21 August 2019 / Published online: 4 September 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Cancer caused by fundamental defects in cell cycle regulation leads to uncontrolled growth of cells. In spite of the treatment with chemotherapeutic agents of varying nature, multiple resistance mechanisms are identifed in cancer cells. Similarly, numerous variations, which decrease the metabolism of chemotherapeutics agents and thereby increasing the toxicity of anticancer drugs have been identifed. 5-Fluorouracil (5-FU) is an anticancer drug widely used to treat many cancers in the human body. Its broad targeting range is based upon its capacity to act as a uracil analogue, thereby disrupting RNA and DNA synthesis. Dihydropyrimidine dehydrogenase (DPD) is an enzyme majorly involved in the metabolism of pyrimidines in the human body and has the same metabolising efect on 5-FU, a pyrimidine analogue. Multiple mutations in the DPD gene have been linked to 5-FU toxicity and inadequate dosages. DPD inhibitors have also been used to inhibit excessive degradation of 5-FU for meeting appropriate dosage requirements. This article focusses on the role of dihydropyrimidine dehydrogenase in the metabolism of the anticancer drug 5-FU and other associated drugs. Keywords Cancer · Anticancer drugs · Dihydropyrimidine dehydrogenase (DPD) · 5-Fluorouracil (5-FU) · Drug resistance · Drug metabolism Introduction by Dihydropyrimidine dehydrogenase (DPD) through the pyrimidine degradation pathway.
    [Show full text]